PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Primary sclerosing cholangitis MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • UDCA – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by product PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Development of affordable PSC drugs • Surrogate endpoints for clinical trials in PSC • siRNA therapeutic products for treatment of PSC PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ALLERGAN • Glenmark • Impax Laboratories • Mylan • TEVA Pharmaceutical PART 16: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global metabolic disorder therapeutic market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn) Global – Year-over-year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2017 Exhibit 17: Pipeline landscape by development phase Exhibit 18: Key clinical trials candidates of primary sclerosing cholangitis Exhibit 19: Product – Market share 2017-2022 (%) Exhibit 20: Comparison by product Exhibit 21: UDCA – Market size and forecast 2017-2022 ($ mn) Exhibit 22: UDCA – Year-over-year growth 2018-2022 (%) Exhibit 23: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Others – Year-over-year growth 2018-2022 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Global – Market share by geography 2017-2022 (%) Exhibit 28: Regional comparison Exhibit 29: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 30: Americas – Year-over-year growth 2018-2022 (%) Exhibit 31: Top 3 countries in Americas Exhibit 32: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 33: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in EMEA Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 36: APAC – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Market opportunity Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: ALLERGAN – Overview Exhibit 45: ALLERGAN – Business segments Exhibit 46: ALLERGAN – Organizational developments Exhibit 47: ALLERGAN – Geographic focus Exhibit 48: ALLERGAN – Segment focus Exhibit 49: ALLERGAN – Key offerings Exhibit 50: ALLERGAN – Key customers Exhibit 51: Glenmark – Overview Exhibit 52: Glenmark – Business segments Exhibit 53: Glenmark– Organizational developments Exhibit 54: Glenmark – Geographic focus Exhibit 55: Glenmark – Segment focus Exhibit 56: Glenmark – Key offerings Exhibit 57: Glenmark – Key customers Exhibit 58: Impax Laboratories – Overview Exhibit 59: Impax Laboratories – Business segments Exhibit 60: Impax Laboratories – Organizational developments Exhibit 61: Impax Laboratories – Geographic focus Exhibit 62: Impax Laboratories – Segment focus Exhibit 63: Impax Laboratories – Key offerings Exhibit 64: Impax Laboratories – Key customers Exhibit 65: Mylan – Overview Exhibit 66: Mylan – Business segments Exhibit 67: Mylan – Organizational developments Exhibit 68: Mylan – Geographic focus Exhibit 69: Mylan – Segment focus Exhibit 70: Mylan – Key offerings Exhibit 71: Mylan – Key customers Exhibit 72: TEVA Pharmaceutical – Overview Exhibit 73: TEVA Pharmaceutical – Business segments Exhibit 74: TEVA Pharmaceutical – Organizational developments Exhibit 75: TEVA Pharmaceutical – Geographic focus Exhibit 76: TEVA Pharmaceutical – Segment focus Exhibit 77: TEVA Pharmaceutical – Key offerings Exhibit 78: TEVA Pharmaceutical – Key customers  

Allergan Glenmark Impax Laboratories Mylan Teva Pharmaceuticals